Growing regulatory pressure and challenge of litigations over adverse or side effects, rapidly changing demographic patterns, drying product pipelines and consistent growth in competition from generic manufacturers are some of the prime challenges faced in the life sciences business. Further growth in cost of drug development, approvals and growing responsibilities and obligations on the regulatory front have driven organizations to adopt outsourcing services for regulatory operations. These activities are proven to result in improved cost efficiencies, while manufacturers becoming more focused on their core competencies. Diversification of several ancillary activities allows organizations to focus in improving core business while the third party vendors deliver optimal services. Some major advantages derived from regulatory affairs outsourcing are increased speed of market approvals, effective maintenance of product success in new and emerging markets, and swift and convenient extension of brand indications and formulations. Regulatory affairs outsourcing is also of high advantage for mid and small size companies that lack expertize in certain departments. This also reduced the work-load on the employees and management while also ensure appropriate timely and prompt regulatory submissions.
"Regulatory writing and publishing to be the major revenue generator, while clinical trial and product registration services to pick pace within the forecast period"
Among the major regulatory affairs outsourcing services, regulatory writing and publishing occupy the largest revenue share in the global market. As the global market is condensing, there is a prominent visibility of distinct regulatory scenarios in different regions. Companies domiciled in Europe and North America often face challenge in terms of regulatory submissions to emerging markets of Asia Pacific, and Middle East & Africa. The regulations worldwide are also changing rapidly due to growing interest to ensure rapid commercialization of products with assured safety profile. Therefore, it has become imperative for manufacturers to provide timely data updating of regulatory submissions and literature. Furthermore, it is anticipated that the market for clinical trials and product registration services shall be witnessing rapid growth during the forecast period. Impending patent expiries, and increasing focus of drug manufacturers on delivering drugs for rare diseases have prompted emergence of pipeline for specialty drugs. With growth in the number of such drug candidates, the demand for clinical trial and product registration services shall be growing in the years to come.
"Asia Pacific to become the global outsourcing hub"
Manufacturers of several blockbuster drugs are domiciled in Europe and North America, where the patents for such drugs are rapidly expiring. In order to enable extension to the product life cycle, several of such manufacturers have increased their efforts in introducing their drugs and medical devices to the emerging markets of Asia Pacific. Companies are harnessing the potential of the emerging economies as an introduction opportunity for their businesses and products in the developed markets. CDMO and regulatory outsourcing activities are being increasingly set up in emerging economies due to cheap labor, improving skills and low service costs.
This report also includes company profiles section that gives insights on the company overview, product portfolio, financial information and key developments of major market players. The major players profiled in this report include ICON plc, Quintiles Transnational Corporation, PAREXEL International Corporation, Covance, Inc., Clinilabs, Inc., Charles River Laboratories International, Inc., Accell Clinical Research, LLC, Criterium, Inc., Medpace, Inc., Promedica International, WuXi App Tec, Genpact Ltd, PRA Health Sciences, Inc. and Pharmaceutical Product Development (PPD), LLC.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Regulatory Affairs Outsourcing Services market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Type
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
